PROVIDE-HF: Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

Trial Profile

PROVIDE-HF: Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; ACE inhibitors; Angiotensin receptor antagonists
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms PROVIDE-HF
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top